Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

References

• Collisson, E.A., Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Kumar N. Taxol-induced polymerization of purified tubulin. J Biol Chem. 1981;256(20):10435–10441.
   PubMed Web of Science ®Google Scholar
• Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmac Ther. 1984;25:83–125.
   PubMed Web of Science ®Google Scholar
• Castedo M, Perfettini J-L, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23(16):2825–2837.
   PubMed Web of Science ®Google Scholar
• Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Current medicinal chemistry. Anti-Cancer Agents. 2005;5(1):65–71.
   Google Scholar
• Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood. 2012;99(6):2060–2069.
   Web of Science ®Google Scholar
• André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–431.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Current Cancer Drug Targets. 2007;7:566–581.
   PubMed Web of Science ®Google Scholar
• Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92(13):1074–1080.
   PubMed Web of Science ®Google Scholar
• Francis PA, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:1238–1244.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24(22):3657–3663.
   PubMed Web of Science ®Google Scholar
• Liu, Z., Wei Z, Hu Y, et al. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. Med Oncol. 2015;32(8):216.
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Matikas A, Koinis F, et al. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. Br J Cancer. 2016;115(7):784–788.
   PubMed Web of Science ®Google Scholar
• Spira AI, Iannotti NO, Savin MA, et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):31–38.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste, J., Breton JL, Bonomi P, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007;25(23):3448–3455.
   PubMed Web of Science ®Google Scholar
• Nayak, L., DeAngelis LM, Robins HI, et al. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer. 2015;121(23):4165–4172.
   PubMed Web of Science ®Google Scholar
• Lam, E.T., Goel S, Schaaf LJ, et al. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;69:523–531.
   PubMed Web of Science ®Google Scholar
• Mohanlal, R., Polikoff J, Reich S. D., et al. The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel. J Clin Oncol. 2016;34(suppl; abstr e20595).
   Google Scholar
• Ng, Q.S., Mandeville H, Goh V, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol. 2012;23(1):231–237.
   PubMed Web of Science ®Google Scholar
• Mauer, A.M., Cohen EE, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(6):631–636.
   PubMed Web of Science ®Google Scholar
• Bollag, D.M., McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–2333.
   PubMed Web of Science ®Google Scholar
• Giaccone G. New drugs in non-small cell lung cancer an overview. Lung Cancer. 1995;12(1):155–3162.
   Web of Science ®Google Scholar
• Preston JN, Trivedi MV. Eribulin: a novel cytotoxic chemotherapy agent. Ann Pharmacother. 2012;46(6):802–811.
   PubMed Web of Science ®Google Scholar
• Lloyd, G.K., Philipp M, Lan H, et al. Abstract A07: plinabulin: evidence for an immune-mediated mechanism of action. Cancer Res. 2016;76:15 Supplement.
   Google Scholar
• Singh AV, Bandi M, Raje N, et al. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011;117(21):5692–5700.
   PubMed Web of Science ®Google Scholar
• Jackson JR, Patrick DR, Dar MM, et al. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer. 2007;7(2):107–117.
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–2327.
   PubMed Web of Science ®Google Scholar
• Donehower RC, Rowinsky EK, Grochow LB, et al. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987;71(12):1171–1177.
   PubMedGoogle Scholar
• Berghmans T, Lafitte JJ, Lecomte J, et al. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer. 2007;96(11):1644–1649.
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Suzuki R, Kataoka K, et al. Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study. Lung Cancer. 2010;69(3):319–322.
   PubMed Web of Science ®Google Scholar
• Sculier JP, Berghmans T, Lafitte JJ, et al. A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer. 2002;37(1):73–77.
   PubMed Web of Science ®Google Scholar
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899–909.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18(19):3390–3399.
   PubMed Web of Science ®Google Scholar
• Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005;16(7):1069–1075.
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19(13):3210–3218.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(21):4285–4291.
   PubMed Web of Science ®Google Scholar
• Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18(3):623–631.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23(1):190–196.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster J-P, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–1088.
   PubMed Web of Science ®Google Scholar
• Zhu J, Sharma DB, Chen AB, et al. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer. 2013;119(11):2048–2060.
   PubMed Web of Science ®Google Scholar
• Joerger M, Von Pawel J, Kraff S, et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016;27(10):1895–1902.
   PubMed Web of Science ®Google Scholar
• Smit EF, Van Meerbeeck JPAM, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol. 2003;21(21):3909–3917.
   PubMed Web of Science ®Google Scholar
• Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010;21(3):540–547.
   PubMed Web of Science ®Google Scholar
• Grossi F, Aita M, Defferrari C, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist. 2009;14(5):497–510.
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27(3):145–157.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103.
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–1597.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol. 2004;22(13):2602–2609.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Androulakis N, Kotsakis A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008;59(1):57–63.
   PubMed Web of Science ®Google Scholar
• Correale, P., Tindara M S, Remondo C, et al. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel ± granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther. 2009;866(15):1–6.
   Google Scholar
• Douillard J-Y, Laporte S, Fossella F, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol. 2007;2(10):939–946.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Pilotto S, Peretti U, et al. Tubulin inhibitors in non-small cell lung cancer: looking back and forward. Expert Opin Pharmacother. 2016;17(8):1113–1129.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23(13):2937–2945.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357(9267):1478–1484.
   PubMed Web of Science ®Google Scholar
• Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006;32(8):583–587.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(11):1377–1382.
   PubMed Web of Science ®Google Scholar
• Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001;6(Suppl 1):4–7.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95(5):362–372.
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16(7):2459–2465.
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12(2):360–367.
   PubMed Web of Science ®Google Scholar
• Camerini, A., Puccetti C, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15(1):359.
   PubMed Web of Science ®Google Scholar
• Katsaounis P, Kotsakis A, Agelaki S, et al. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol. 2015;75(4):821–827.
   PubMed Web of Science ®Google Scholar
• Fløtten O, Grønberg BH, Bremnes R, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012;107(3):442–447.
   PubMed Web of Science ®Google Scholar
• Farhat FS, Ghosn MG, Kattan JG. Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2015;76(2):235–242.
   PubMed Web of Science ®Google Scholar
• Hirsh V, Okamoto I, Hon JK, et al. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(1):83–90.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–2062.
   PubMed Web of Science ®Google Scholar
• Bertino EM, Williams TM, Nana-Sinkam SP, et al. Stromal caveolin-1 is associated with response and survival in a phase II trial of nab-paclitaxel with carboplatin for advanced NSCLC patients. Clin Lung Cancer. 2015;16(6):466–474.
   PubMed Web of Science ®Google Scholar
• Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol. 2010;5(10):1529–1535.
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Tsao-Wei DD, Groshen S, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012;7(3):574–578.
   PubMed Web of Science ®Google Scholar
• Edelman, M.J., Schneider CP, Tsai CM, et al. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol. 2013;31(16):1990–1996.
   PubMed Web of Science ®Google Scholar
• Martínez-Díez, M., Guillén-Navarro MJ, Pera B, et al. PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochem Pharmacol. 2014;88(3):291–302.
   PubMed Web of Science ®Google Scholar
• Beer, T.M., Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs. 2007;25(6):565–570.
   PubMed Web of Science ®Google Scholar
• Dong, M., Liu F, Zhou H, et al. Novel natural product- and privileged scaffold-based tubulin inhibitors targeting the colchicine binding site. Molecules. 2016;21(10):1375. doi:10.3390/molecules21101375.
   Web of Science ®Google Scholar
• Thomopoulou, P., Sachs J, Teusch N, et al. New colchicine-derived triazoles and their influence on cytotoxicity and microtubule morphology. ACS Med Chem Lett. 2016;7(2):188–191.
   PubMed Web of Science ®Google Scholar
• Zefirova ON, Lemcke H, Lantow M, et al. Unusual tubulin-clustering ability of specifically c7-modified colchicine analogues. Chembiochem. 2013;14(12):1444–1449.
   PubMed Web of Science ®Google Scholar
• Thomas E, Gopalakrishnan V, Hegde M, et al. A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. Sci Rep. 2016;6:34653.
   PubMed Web of Science ®Google Scholar
• Teraishi F, Wu S, Sasaki J, et al. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell Mol Life Sci. 2005;62(19–20):2382–2389.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhai S, Li L, et al. P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model. J Pharmacol Sci. 2014;126(1):66–76.
   PubMed Web of Science ®Google Scholar
• Mu Y, Liu Y, Xiang J, et al. From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor. Cell Death Dis. 2016;7:e2143.
   Google Scholar
• Yan J, Pang Y, Sheng J, et al. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Biochem Pharmacol. 2015;97(1):51–61.
   PubMed Web of Science ®Google Scholar
• Chang L-C, Yu Y-L, Liu C-Y, et al. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1. Cancer Chemother Pharmacol. 2015;75(6):1303–1315.
   PubMed Web of Science ®Google Scholar
• Viola G, Bortolozzi R, Hamel E, et al. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol. 2012;83(1):16–26.
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Chen X, Fan -X-X, et al. Compound library screening identified cardiac glycoside digitoxin as an effective growth inhibitor of gefitinib-resistant non-small cell lung cancer via downregulation of alpha-tubulin and inhibition of microtubule formation. Molecules. 2016;21(3):374.
   PubMed Web of Science ®Google Scholar
• Cisternino S, Bourasset F, Archimbaud Y, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol. 2003;138(7):1367–1375.
   PubMed Web of Science ®Google Scholar
• Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723–730.
   PubMed Web of Science ®Google Scholar
• Vrignaud P, Sémiond D, Lejeune P, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013;19(11):2973–2983.
   PubMed Web of Science ®Google Scholar
• Waller CF, Vynnychenko I, Bondarenko I, et al. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2015;16(2):92–99.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Shvartsbeyn M. Epothilones in development for non–small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer. 2012;13(3):171–180.
   PubMed Web of Science ®Google Scholar
• Gridelli, C., Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist. 2009;14(6):612–620.
   PubMed Web of Science ®Google Scholar
• Gadgeel, S., Stevenson J, Gandhi L, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. J Clin Oncol. 2016;9016(339).
   Google Scholar
• George, B., Kelly K, Ko A, et al. P1.46: phase I study of nivolumab + nab-paclitaxel in solid tumors: preliminary analysis of the non-small cell lung cancer cohort. J Thorac Oncol. 2016;11(10):S211–S212.
   Google Scholar
• Rizvi, N.A., Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979.
   PubMed Web of Science ®Google Scholar
• Liu, S.V., Powderly J. D., Camidge D. R, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33:suppl; abstr 8030.
   Web of Science ®Google Scholar
• Ramakrishnan, R., Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Investig. 2010;120(4):1111–1124.
   PubMed Web of Science ®Google Scholar
• van der Most, R.G., Assudani D, Nagaraj S, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One. 2009;4(9).
   PubMed Web of Science ®Google Scholar
• Galluzzi, L., Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.
   PubMed Web of Science ®Google Scholar
• Ménard, C., Martin F, Apetoh L, et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother. 2008;57(11):1579–1587.
   PubMed Web of Science ®Google Scholar
• Li, J.-Y., Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014;286170:1–10.
   Google Scholar
• Senovilla, L., Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678–1684.
   PubMed Web of Science ®Google Scholar
• Pfannenstiel, L.W., Lam SS, Emens LA, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010;263:79–87.
   PubMed Web of Science ®Google Scholar
• Aymeric, L., Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010;70(3):855–858.
   PubMed Web of Science ®Google Scholar
• Haynes, N.M., van der Most RG, Lake RA, et al. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol. 2008;20(5):545–557.
   PubMed Web of Science ®Google Scholar
• Shurin, G.V., Tourkova IL, Kaneno R, et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009;183(1):137–144.
   PubMed Web of Science ®Google Scholar
• Martino, E., Misso G, Pastina P, et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2016;2:16025.
   PubMedGoogle Scholar
• Sandler, A., Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. New England J Med. 2006;355(24):2542–2550.
   PubMed Web of Science ®Google Scholar
• Garon, E.B., Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. The Lancet. 2014;384(9944):665–673.
   PubMed Web of Science ®Google Scholar
• Sutiman N, Zhang Z, Tan EH, et al. Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules. PLoS One. 2016;11(5):e0154316.
   PubMed Web of Science ®Google Scholar
• Tan EH, Tan DSW, Li WY, et al. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer. 2015;88(3):289–296.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155.
   PubMed Web of Science ®Google Scholar
• Roda, D., Geuna E, Rafii S, et al. TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. J Clin Oncol. 2014;32:5s(suppl; abstr 2607).
   Google Scholar
• Janne PA, van den Heuvel M, Barlesi F, et al., Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial. Ann Oncol. 2016;27(suppl_6):LBA47_PR.
   Google Scholar
• Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015;26(8):1741–1748.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Fennel D, Kovcin V, et al.  PL03.09: Phase 3 study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small cell lung cancer (GALAXY-2). J Thor Oncol. 2017;12(1):S7–S8.
   Google Scholar
• Heist, R.S., Aren, O. R., Mita, A. C, et al. Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC). |2014 ASCO Annual Meeting |abstracts |meeting Library. J Clin Oncol. 2014;32:5s(abstr 8054).
   PubMed Web of Science ®Google Scholar
• Langer, C.J., Socinski, M. A., Patel, J. D, et al. Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous non–small cell lung cancer. Am J Clin Oncol. 2016;39(5):441–447.
   PubMed Web of Science ®Google Scholar
• Botta, C., Barbieri, V., Ciliberto, D, et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther. 2013;14(6):469–475.
   PubMed Web of Science ®Google Scholar
• Correale, P., Botta, C., Basile, A, et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 2011;12(2):112–118.
   PubMed Web of Science ®Google Scholar
• Correale, P., Remondo, C., Carbone, S. F, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 2010;9(9):685–693.
   PubMed Web of Science ®Google Scholar
• Petrioli R, Francini E, Fiaschi AI, et al. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol. 2015;32(4):134.
   PubMed Web of Science ®Google Scholar
• Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):311–319.
   PubMed Web of Science ®Google Scholar
• Thavasu, P., Rodriguez, B. J., Basu, B, et al. Abstract CT138: translating preclinical observations to the clinic: combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. Cancer Res. 2015;75(suppl 15):CT138.
   Google Scholar
• Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761–772.
   PubMed Web of Science ®Google Scholar
• Proia DA, Sang J, He S, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 2012;30(6):2201–2209.
   PubMed Web of Science ®Google Scholar
• Hammerman, P.S., Lawrence MS, Voet D, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–525.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Johnson GL. MEK inhibition in non-small cell lung cancer. Lung Cancer. 2014;86(2):121–125.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38–47.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Anderson I, Bauer TM, et al. A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG +), locally advanced or metastatic non-small cell lung cancer (NSCLC). Ann Oncol. 2016;27(suppl 6):416–454.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265.
   PubMed Web of Science ®Google Scholar
• Zhou WJ, Zhang X, Cheng C, et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol. 2012;166(5):1669–1683.
   PubMed Web of Science ®Google Scholar
• Monzó M, Rosell R, Sánchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17(6):1786–1793.
   PubMed Web of Science ®Google Scholar
• Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst. 2001;93(24):1886–1888.
   PubMedGoogle Scholar
• De Castro J, Belda-Iniesta C, Cejas P, et al. New insights in beta-tubulin sequence analysis in non-small cell lung cancer. Lung Cancer. 2003;41(1):41–48.
   PubMed Web of Science ®Google Scholar
• Sale S, Sung R, Shen P, et al. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther. 2002;1(3):215–225.
   PubMed Web of Science ®Google Scholar
• Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 2004;5(3):158–164.
   PubMed Web of Science ®Google Scholar
• Ganguly A, Cabral F. New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta. 2011;1816(2):164–171.
   PubMed Web of Science ®Google Scholar
• Kamath K, Wilson L, Cabral F, et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005;280(13):12902–12907.
   PubMed Web of Science ®Google Scholar
• Xie S, Ogden A, Aneja R, et al. Microtubule-binding proteins as promising biomarkers of paclitaxel sensitivity in cancer chemotherapy. Med Res Rev. 2016;36(2):300–312.
   PubMed Web of Science ®Google Scholar
• Kanakkanthara A, Miller JH. MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev. 2013;39(2):161–170.
   PubMed Web of Science ®Google Scholar
• Catuogno S, Cerchia L, Romano G, et al. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene. 2013;32(3):341–351.
   PubMed Web of Science ®Google Scholar
• Liu Z-L, Wang H, Liu J, et al. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 2013;372(1–2):35–45.
   PubMed Web of Science ®Google Scholar
• Du L, Subauste MC, DeSevo C, et al. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 2012;7(6):e39167.
   Google Scholar
• Chen D, Huang J, Zhang K, et al. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 2014;50(17):3050–3067.
   PubMed Web of Science ®Google Scholar
• Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008;9(2):168–175.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Ruan L, Zheng L-M, et al. Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2012;77(1):9–15.
   PubMed Web of Science ®Google Scholar
• Yang YL, Luo XP, Xian L, et al. The prognostic role of the class III beta-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PLoS One. 2014;9(4):e93997.
   Google Scholar
• Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003;22(23):3548–3553.
   PubMed Web of Science ®Google Scholar
• Sève P, Isaac S, Trédan O, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 2005;11(15):5481–5486.
   PubMed Web of Science ®Google Scholar
• Ho C-C, Kuo S-H, Huang P-H, et al. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59(1):105–110.
   PubMed Web of Science ®Google Scholar
• Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005;102:8315–8320.
   PubMed Web of Science ®Google Scholar
• Bauer JA, Chakravarthy AB, Rosenbluth JM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010;16(2):681–690.
   PubMed Web of Science ®Google Scholar
• Alli E, Bash-Babula J, Yang J-M, et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002;62(23):6864–6869.
   PubMed Web of Science ®Google Scholar
• Su D, Smith SM, Preti M, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 2009;115(11):2453–2463.
   PubMed Web of Science ®Google Scholar
• Luo Y, Li D, Ran J, et al. End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability. Protein Cell. 2014;5(6):469–479.
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Stinchcombe TE, Fried DB, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007;2(9):845–853.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology.  NSCLC Version 3.2017.  Abstract available at https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar